Shandong Xinhua Pharmaceutical Bilan de santé

Santé financière contrôle des critères 6/6

Shandong Xinhua Pharmaceutical possède un total de capitaux propres de CN¥5.1B et une dette totale de CN¥1.7B, ce qui porte son ratio d'endettement à 32.5%. Son actif total et son passif total sont CN¥8.8B et de CN¥3.7B. L'EBIT de Shandong Xinhua Pharmaceutical est CN¥476.7M ce qui fait que son ratio de couverture des intérêts 26. Elle dispose de liquidités et de placements à court terme de CN¥1.2B.

Informations clés

32.5%

Ratio d'endettement

CN¥1.66b

Dette

Ratio de couverture des intérêts	26x
Argent liquide	CN¥1.16b
Fonds propres	CN¥5.10b
Total du passif	CN¥3.73b
Total des actifs	CN¥8.82b

Mises à jour récentes de la santé financière

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27

Recent updates

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Jun 28

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Jan 23

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Mar 07

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 18

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Jul 27

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Jul 04

Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)

Mar 09

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Dec 21

Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?

Apr 06

What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?

Mar 19

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Feb 26

Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 05

Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years

Jan 18

Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?

Dec 29

Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?

Dec 14

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Nov 26

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 719 ( CN¥3.6B ) dépassent ses passifs à court terme ( CN¥2.7B ).

Passif à long terme: Les actifs à court terme de 719 ( CN¥3.6B ) dépassent ses passifs à long terme ( CN¥1.0B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 719 ( 9.8% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 719 a été réduit de 47.7% à 32.5% au cours des 5 dernières années.

Couverture de la dette: La dette de 719 est bien couverte par le flux de trésorerie opérationnel ( 26.8% ).

Couverture des intérêts: Les paiements d'intérêts de 719 sur sa dette sont bien couverts par l'EBIT ( 26 x couverture).

Shandong Xinhua Pharmaceutical Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt

Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Recent updates

Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application

Investor sentiment improves as stock rises 16%

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application

Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs

Upcoming dividend of HK$0.027 per share

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023)

Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024

Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year

Dividend of HK$0.27 announced

Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022)

Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient

Now 21% overvalued

Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price

Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023

Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation

Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation

Upcoming dividend of HK$0.22 per share at 3.6% yield

Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs

Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021)

Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022

These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.18 per share

Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager

Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020)

Now 21% undervalued after recent price drop